Abstract
Kawasaki disease (KD) is the most common cause of acquired heart disease in children in Japan, North America and Europe. It is now being increasingly recognized from the developing countries as well. If not diagnosed and treated in time, KD can result in coronary artery abnormalities in approximately 15–25 % cases. The long-term consequences of these abnormalities may manifest in adults as myocardial ischemia and congestive heart failure. Intravenous immunoglobulin (IVIg) remains the drug of choice for treatment of KD, but several new agents like infliximab, cyclosporine, glucocorticoids and statins are now being increasingly used in these patients. While echocardiography has been the preferred imaging modality hitherto, CT coronary angiography has emerged as an exciting new supplementary option and provides an entirely new dimension to this disease. The incidence of KD has shown a progressive increase in several countries and it is likely that this disease would impact public health programmes in the near future even in the developing countries.
Similar content being viewed by others
References
Sundel RP, Petty RE. Kawasaki disease. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of Pediatric Rheumatology. 6th ed. Philadelphia: Elsevier Saunders; 2011. p. 505–20.
Uehara R, Belay ED. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J Epidemiol. 2012;22:79–85.
Kumar RK, Tandon R. Rheumatic fever & rheumatic heart disease: the last 50 years. Indian J Med Res. 2013;137:643–58.
Burns JC, Kushner HI, Bastian JF, et al. Kawasaki disease: a brief history. Pediatrics. 2000;106:E27.
Singh S, Kawasaki T. Kawasaki disease-an Indian perspective. Indian Pediatr. 2009;46:563–71.
Singh S, Aulakh R, Bhalla AK, Suri D, Manojkumar R, Burns JC. Is Kawasaki disease incidence rising in Chandigarh, North India? Arch Dis Child. 2011;96:137–40.
Singh S, Aulakh R, Kawasaki T. Kawasaki disease and the emerging coronary artery disease epidemic in India: is there a correlation? Indian J Pediatr. 2014; 81: 328-32.
Singh S, Bansal A, Gupta A, Kumar RM, Mittal BR. Kawasaki disease: a decade of experience from North India. Int Heart J. 2005;46:679–89.
Kawasaki T Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi. 1967;16:178–222.
Dean AG, Melish ME, Hick R, Palumbo NE. An epidemic of Kawasaki syndrome in Hawaii. J Pediatr. 1982;100:552–7.
Yanagawa H, Nakamura Y, Ojima T, Yashiro M, Tanihara S, Oki I. Changes in epidemic patterns of Kawasaki disease in Japan. Pediatr Infect Dis J. 1999;18:64–6.
Yanagawa H, Yashiro M, Nakamura Y, Kawasaki T, Kato H. Results of 12 nationwide epidemiological incidence surveys of Kawasaki disease in Japan. Arch Pediatr Adolesc Med. 1995;149:779–83.
Yanagawa H, Yashiro M, Nakamura Y, Kawasaki T, Kato H. Epidemiologic pictures of Kawasaki disease in Japan: from the nationwide incidence survey in 1991 and 1992. Pediatrics. 1995;95:475–9.
Yanagawa H, Nakamura Y, Yashiro M, Ojima T, Koyanagi H, Kawasaki T. Update of the epidemiology of Kawasaki disease in Japan: from the results of 1993–1994 nationwide survey. J Epidemiol. 1996;6:148–57.
Yanagawa H, Nakamura Y, Yashiro M, et al. Results of the nationwide epidemiologic survey of Kawasaki disease in 1995 and 1996 in Japan. Pediatrics. 1998;102:E65.
Rodo X, Ballester J, Cayan D, et al. Association of Kawasaki disease with tropospheric wind patterns. Sci Rep. 2011;1:152.
Burns JC, Herzog L, Fabri O, et al. Kawasaki Disease Global Climate Consortium. Seasonality of Kawasaki disease: a global perspective. PLoS One. 2013;8:e74529.
Philip S, Lee W-C, Liu S-K, Wu M-H, Lue H-C. A swine model of horse-serum induced coronary vasculitis: an implication for Kawasaki disease. Pediatr Res. 2004;55:211–9.
Philip S, Lee W-C, Wu M-H, Cherian KM, Lue H-C. Histopathological evaluation of horse serum induced immune complex vasculitis in swine: implication to coronary artery lesions in Kawasaki disease. Pediatr Neonatol. 2014;55:297–305.
Burns JC, Newburger JW. Genetics insights in to the pathogenesis of Kawasaki disease. Circ Cardiovasc Genet. 2012;5:277–8.
Shrestha S, Wiener H, Shendre A, et al. Role of activating FCVR gene polymorphisms in Kawasaki disease susceptibility and intravenous immunoglobulin response. Circ Cardiovasc Genet. 2012;5:309–16.
Son MB, Newburger JW. Kawasaki disease. In: Kliegman, Stanton, St. Geme Schor, Behrman A, editors. Nelson Textbook of Pediatrics. 19th ed. Philadelphia: Elsevier Saunders; 2011. p. 862-7.
Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment and long-term management of Kawasaki disease. Circulation. 2004;110:2747–71.
Achenbach S, Marwan M, Ropers D, et al. Coronary computed tomography angiography with a consistent dose below 1 mSv using prospectively electrocardiogram-triggered high-pitch spiral acquisition. Eur Heart J. 2010;31:340–6.
Dominguez SR, Anderson MS. Advances in the treatment of Kawasaki disease. Curr Opin Pediatr. 2013;25:103–9.
Okada K, Hara J, Maki I, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr. 2009;168:181–5.
Okada Y, Shinohara M, Kobayashi T, et al. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr. 2003;143:363–7.
Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007;356:663–75.
Tremoulet AH, Jain S, Jaggi P, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet. 2014;383:1731–8.
Lau AC, Duong TT, Ito S, Wilson GJ, Yeung RS. Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease. Clin Exp Immunol. 2009;157:300–9.
Suzuki H, Terai M, Hamada H, et al. Cyclosporin a treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J. 2011;30:871–6.
Sleeper LA, Minich LL, McCrindle BM, et al. Evaluation of Kawasaki disease risk scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011;158:831–5.
Tewelde H, Yoon J, Van Ittersum W, Worley S, Preminger T, Goldfarb J. The Harada Score in the US population of children with Kawasaki disease. Hosp Pediatr. 2014;4:233–8.
Rizk SR, El Said G, Daniels LB, et al. Acute myocardial ischemia in adults secondary to missed Kawasaki disease in childhood. Am J Cardiol. 2015;115:423–7.
Gordon JB, Kahn AM, Burns JC. When children with Kawasaki disease grow up: myocardial and vascular complications in adulthood. J Am Coll Cardiol. 2009;54:1911–20.
Acknowledgments
The authors express their gratitude to Dr. Jane Burns, Dr. Marian Melish, Dr. Ross Petty, and Dr. John Gordon who participated as faculty from overseas in the 3rd. Kawasaki Disease Summit, Chandigarh, October 2014.
Guarantor
SS will act as guarantor for this paper.
Conflict of Interest
None.
Source of Funding
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Singh, S., Sharma, D., Bhattad, S. et al. Recent Advances in Kawasaki Disease – Proceedings of the 3rd Kawasaki Disease Summit, Chandigarh, 2014. Indian J Pediatr 83, 47–52 (2016). https://doi.org/10.1007/s12098-015-1858-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-015-1858-4